Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- AVCT.LSE
- Price
- 38.00
- Stock movement up
- +- (%)
- Company name
- Avacta Group PLC
- Exchange
- (LSE ,
- Currency
- GBX )
- Sector
- Healthcare >Biotechnology
- Market cap
- 13.93B
- Ent value
- 13.94B
- Price/Sales
- 403.61
- Price/Book
- 289.19
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 0.88%
- 1 year return
- -25.12%
- 3 year return
- -30.25%
- 5 year return
- -10.18%
- 10 year return
- -7.79%
Last updated: 2025-04-12
DIVIDENDS
AVCT.LSE does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 403.61 |
| Price to Book | 289.19 |
| EV to Sales | 403.86 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 366.52M |
| EPS (TTM) | -0.11 |
| FCF per share (TTM) | -0.10 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 34.51M |
| Gross profit (TTM) | 12.58M |
| Operating income (TTM) | -42.05M |
| Net income (TTM) | -37.42M |
| EPS (TTM) | -0.11 |
| EPS (1y forward) | -0.08 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 36.47% |
| Operating margin (TTM) | -121.87% |
| Profit margin (TTM) | -108.44% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 32.53M |
| Net receivables | 10.31M |
| Total current assets | 45.45M |
| Goodwill | 0.00 |
| Intangible assets | 30.18M |
| Property, plant and equipment | 0.00 |
| Total assets | 89.29M |
| Accounts payable | 10.13M |
| Short/Current long term debt | 25.30M |
| Total current liabilities | 35.27M |
| Total liabilities | 41.13M |
| Shareholder's equity | 48.16M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -31.22M |
| Capital expenditures (TTM) | 2.08M |
| Free cash flow (TTM) | -33.34M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -77.69% |
| Return on Assets | -41.91% |
| Return on Invested Capital | -51.05% |
| Cash Return on Invested Capital | -45.49% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 38.00 |
| Daily high | 39.00 |
| Daily low | 37.00 |
| Daily Volume | 828K |
| All-time high | 1140.00 |
| 1y analyst estimate | 89.50 |
| Beta | 1.18 |
| EPS (TTM) | -0.11 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 28 Apr 2025 |
Downside potential
Loading...
Downside potential data
| AVCT.LSE | S&P500 | |
| Current price drop from All-time high | -96.67% | -12.89% |
| Highest price drop | -99.12% | -56.47% |
| Date of highest drop | 9 Mar 2006 | 9 Mar 2009 |
| Avg drop from high | -88.00% | -11.07% |
| Avg time to new high | 1147 days | 12 days |
| Max time to new high | 4579 days | 1805 days |
COMPANY DETAILS
Marketcap
13.93B
Marketcap category
Large-cap
Description
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Employees
154
Website
Investor relations
-
SEC filings
CEO
Country
UK
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found